Idexx Laboratories Inc /de (IDXX) · Aug 4, 2026 · Earnings

EPS beat and full-year outlook rose, despite softer instrument revenue

Beat — Comparable EPS $4.07 vs ~$4.02 consensus

EPS beat and full-year outlook rose, despite softer instrument revenue

The quarter was a modest EPS beat, not a broad upside surprise. Comparable EPS reached $4.07 versus the published consensus of roughly $4.02, while revenue of $1.217 billion was approximately in line with the roughly $1.22 billion expectation.

MetricQ2 2026Prior year / expectation
Revenue$1.217B (Income Statement)$1.109B prior year; ~$1.22B consensus
Comparable EPS$4.07 (EPS reconciliation)$3.53 prior year; ~$4.02 consensus
Comparable operating margin34.7% (Financial Highlights)33.6% prior year
Organic revenue growth9.0% (Revenue growth tables)8.5% midpoint of updated FY guidance

Underlying recurring revenue remained the main engine. CAG Diagnostics recurring revenue grew 10% organically, with IDEXX VetLab consumables up 14% and reference laboratory services up 10%; that offset a 20% organic decline in capital instrument revenue as the company lapped last year's inVue Dx rollout. (CAG revenue tables)

Profitability was better than the headline growth rate suggests. Comparable operating margin expanded 110 basis points to 34.7%, supported by recurring-revenue mix, productivity, and pricing; comparable operating profit grew 12%, ahead of comparable revenue growth of 9%. (Financial Highlights)

Management raised the full-year framework, giving the report its clearest incremental signal. Revenue guidance moved to $4.700-$4.745 billion from $4.675-$4.760 billion, lifting the midpoint by $5 million despite a $15 million foreign-exchange headwind. Organic-growth guidance rose to 8.5%-9.7% from 7.7%-9.7%, while the operating-margin range increased to 32.3%-32.5% from 32.1%-32.5% and EPS to $14.69-$14.94 from $14.45-$14.90. (2026 Growth and Financial Performance Outlook)

Net: narrowly better than expected, with quality improving through recurring revenue and margins. The revenue result itself was not a meaningful beat, and capital instruments remain weak, but the EPS outperformance plus higher organic-growth, margin, and EPS outlooks make this more than an in-line quarter.

What to watch next

Investor Day, August 13, 2026

Original filing on SEC EDGAR

More Idexx Laboratories Inc /de news

EPS beat and full-year outlook rose, despite softer instrument revenue | IDXX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.